Literature DB >> 11782460

Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival.

Qunxing Ding1, Jennifer J Lewis, Kenneth M Strum, Edgardo Dimayuga, Annadora J Bruce-Keller, Jay C Dunn, Jeffrey N Keller.   

Abstract

Huntington's disease (HD) is one of eight established triplet repeat neurodegenerative disorders, which are collectively caused by the genetic expansion of polyglutamine repeats. While the mechanism(s) by which polyglutamine expansion causes neurodegeneration in each of these disorders is being intensely investigated, the underlying cause of polyglutamine toxicity has not been fully elucidated. A number of studies have focused on the potential role of protein aggregation and disruption of the proteasome proteolytic pathway in polyglutamine-mediated neurodegeneration. However, at present it is not clear whether polyglutamine-mediated protein aggregation is sufficient to induce cell death, nor has it been clearly determined whether proteasome inhibition precedes, coincides, or occurs as the result of the formation of polyglutamine-associated protein aggregation. To address these important components of polyglutamine toxicity, in the present study we utilized neural SH-SY5Y cells stably transfected with polyglutamine-green fluorescent protein constructs to examine the effects of polyglutamine expansion on protein aggregation, proteasome activity, and neural cell survival. Data from the present study demonstrate that polyglutamine expansion does not dramatically impair proteasome activity or elevate protein aggregate formation under basal conditions, but does significantly impair the ability of the proteasome to respond to stress, and increases stress-induced protein aggregation following stress, all in the absence of neural cell death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782460     DOI: 10.1074/jbc.M107706200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

Review 2.  Immunoproteasomes: structure, function, and antigen presentation.

Authors:  Deborah A Ferrington; Dale S Gregerson
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.

Authors:  Lianwu Fu; Ya-sheng Gao; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2005-06-16       Impact factor: 5.996

4.  Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Sunita Gupta; Jeffrey N Keller; Pamela E Knapp; Kurt F Hauser; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2008-11-19       Impact factor: 5.372

Review 5.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 6.  Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease.

Authors:  Ashok N Hegde; Sudarshan C Upadhya
Journal:  Biochim Biophys Acta       Date:  2010-08-03

7.  Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.

Authors:  Siddhartha Mitra; Andrey S Tsvetkov; Steven Finkbeiner
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

8.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

9.  Enhanced toxicity to the catecholamine tyramine in polyglutamine transfected SH-SY5Y cells.

Authors:  Rebecca R Smith; Edgardo R Dimayuga; Jeffrey N Keller; William F Maragos
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

10.  Modulation of SCF beta-TrCP-dependent I kappaB alpha ubiquitination by hydrogen peroxide.

Authors:  Sami Banerjee; Jaroslaw W Zmijewski; Emmanuel Lorne; Gang Liu; Yonggang Sha; Edward Abraham
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.